Table 4 shows that compared with noninsulin-treated patients and after adjustment, those receiving insulin therapy were 2-3-fold more likely to have CKD stages 4-5, retinopathy, peripheral neuropathy, and 5.06-fold (95% CI 1.20-21.38) more to have undergone podiatry review. The gene discussed is INS; the disease is peripheral neuropathy.